hca-i

hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual inhibitor of human carbonic anhydrase I (hCA-I) and human carbonic anhydrase II (hCA-II), with Ki values of 0.22 μM and 0.33 μM respectively. hCA-I/hCA-II-IN-1 is useful for research into diseases related to CA enzymes, including glaucoma, hypertension, and ulcers.

Histone acetyltransferase p300 Inhibitor 4c is a 2-aminothiazole derivative. Histone acetyltransferase p300 Inhibitor 4c inhibited hCA I, hCA II, AChE and BChE with Ki values of 0.008 ± 0.001, 0.124 ± 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 µM. 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM.

Methazolamide (CL 8490) is a carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

hCAIX-IN-5 was a selective hCAIX inhibitor, inhibiting hCAI, hCAII, hCAIV, and hCAIX with Ki values of >10000, >10000, 130.7, and 829.1 nM, respectively.

hCAI/II-IN-10 (Compound 5d) is an inhibitor of human carbonic anhydrase I and II (hCA I and hCA II), with IC50 values of 4.32 nM and 3.89 nM, respectively.

hCAI/II-IN-8 (Compound 8) is a hydrazone derivative originating from 4-hydroxybenzaldehyde. It primarily inhibits human carbonic anhydrase isoenzymes I (hCA I) and II (hCA II) with IC50 values of 21.35 ± 0.39 nM for hCA I and 7.12 ± 0.12 nM for hCA II. It also exhibits inhibitory effects on AChE and BChE, with IC50 values of 46.27 ± 0.75 nM and 43.38 ± 0.83 nM, respectively.

hCAI/II-IN-2 (compound 2b) is a highly effective dual inhibitor of human carbonic anhydrase I and II (hCA I/II), with Ki values of 40.97 nM for hCA I, 15.15 nM for hCA II, and 61.88 nM for hCA IX. With its anti-hypoxic properties, hCAI/II-IN-2 demonstrates activity against acute mountain sickness (AMS) and exhibits low cellular activity [1].

hCAI/II-IN-4 (compound 6d) is a potent inhibitor of both hCA I and hCA II enzymes, with Ki values of 16.95 nM and 15.22 nM, respectively. It also inhibits hCA IX with a Ki value of 27.04 nM, exhibits anti-hypoxia properties, and maintains low toxicity. This compound is suitable for investigating acute mountain sickness (AMS) in research studies [1].

hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and ＞50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy.

hCAI/II-IN-3 (compound 5b) is a highly effective dual inhibitor of hCA I/II enzymes, exhibiting Ki values of 51.25, 13.15, and 42.18 nM for hCA I, hCA II, and hCA Ⅸ, respectively. It demonstrates anti-hypoxic properties against acute mountain sickness (AMS) and exhibits low cellular activity [1].

hCAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA I/II) inhibitor, with an IC50 value of 0.047 μM for hCA I and 0.024 μM for hCA II.

hCAI/II-IN-5 is a potent inhibitor of hCA I and hCA II (human carbonic anhydrase isozymes I and II), with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also inhibits α-Glycosidase (IC50: 48.98 nM) and AChE (IC50: 420.14 nM). nM). hCAI/II-IN-5 can be used in the study of diabetes, heart failure, Alzheimer's disease, ulcers, epilepsy and many other diseases.

hCAI/II-IN-7 (compound 1F) is an effective carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM, and 21 μM for hCA-I, hCA-II, and bCA respectively.

hCAI/II/XII-IN-1 (compound 7) is an inhibitor of human carbonic anhydrases hCAI, hCAII, and hCAXII, with Ki values of 78.5 nM, 9.1 nM, 605 nM, 7.7 nM, and 3.7 nM.

hCAI/II-IN-11 (compound 2c) is a carbonic anhydrase inhibitor with IC50 values of 12.56 μM and 13.02 μM for hCAI and hCA II, respectively. In addition, hCAI/II-IN-11 exhibits antioxidant and antibacterial properties.

hCA-IN-1 (Compound 5u) is an hCA inhibitor with Ki values of 159.2 nM for hCA I, 4.8 nM for hCA II, 15.5 nM for CAIX, and 2 nM for CAXII. It demonstrates broad-spectrum anticancer activity against melanoma, breast cancer, and colon cancer cells. ADME predictions indicate that hCA-IN-1 has good solubility and oral bioavailability. This compound is useful in tumor research.

Fluorometholone Acetate (Oxylone acetate) is a synthetic corticosteroid, used in the treatment of steroid responsive inflammatory conditions of the eye.

Compound CDy9 is a highly selective inhibitor of carbonic anhydrase (CA) with an IC50 value of 0.18 μM for hCA II.

hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. It is not blood-brain barrier permeable.

hCAI/II/IV-IN-28(WAY-638358) is a potent carbonic anhydrase inhibitor with potential anticonvulsant activity.

hCAIX/XII-IN-13 functions as an inhibitor targeting specific human carbonic anhydrases (hCA) IX and XII, crucial in tumor-related processes. Demonstrating efficacy, this compound offers inhibitory K i values of 0.08 µM for IX and 0.06 µM for XII. Additionally, under hypoxic conditions, hCAIX/XII-IN-13 enhances the effectiveness of Doxorubicin on MCF-7 cells by promoting G2/M phase cell cycle arrest and increasing apoptosis.

hCA I-IN-4 (Compound 14) is an inhibitor of carbonic anhydrase and cholinesterase, effectively inhibiting hCA I, hCA II, AChE, and BChE with Ki values of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nM, respectively. It also demonstrates cytotoxicity in BT-549 cells, with an IC50 of 16.59 μM.

AChE/hCA I-IN-1 (Compound L3) is an inhibitor of acetylcholinesterase (AChE) and carbonic anhydrase (CA), effectively inhibiting AChE, hCA I, and hCA II with IC50 values of 302 nM, 265 nM, and 283 nM, respectively.

hCAIX/XII-IN-9 (compound 8) is a potent inhibitor of carbonic anhydrase (CA), with Ki values of 1658 nM for hCA I, 184.8 nM for hCA II, 8.9 nM for hCA IX, and 64.8 nM for hCA XII.